Original Title: 치매진단에 있어 뇌 FDG PET검사의 진단적 유용성 평가 연구

Authors' recommendations: We assessed the diagnostic accuracy of FDG-PET in the evaluation of dementia, which is known as a tool for detecting reduced glucose metabolism in a patient's brain even before the development of dementia symptoms. To evaluate diagnostic accuracy in the early detection of dementia and Alzheimer's disease, we conducted systematic reviews of published articles, and identified 9 cross-sectional studies and 13 delayed cross-sectional studies. In addition, we collected information from the medical charts of amnestic mild cognitive impairment (MCI) patients in a study site and followed them up for two years retrospectively. We then evaluated the diagnostic accuracy of FDG-PET with MRI. Meta-analysis of the 9 cross-sectional studies resulted in a pooled sensitivity (SN) of 0.61 (95% CI:0.42-0.79), a pooled specificity (SP) of 0.81 (95% CI: 0.55-1.07). In the 13 delayed cross-section studies, it resulted in a pooled SN of 0.81 (95% CI: 0.72-0.91) and a pooled SP of 0.78 (95% CI: 0.65-0.92). With subgroup analyses in amnestic mild cognitive impairment (MCI) patients, the result suggested a pooled SN of 0.92 (95% CI: 0.75-1.00), a pooled SP of 0.88 (95% CI: 0.77-0.98). In the outcome analysis of the retrospective cohort, MRI resulted in an SN of 0.37 (95% CI: 0.19-0.59), an SP of 0.69 (95% CI: 0.52-0.81), and an accuracy of 0.57 (95% CI: 0.44-0.71) with an area under the curve (AUC) of 0.53 (95% CI: 0.39-0.66), whereas FDG-PET showed an SN of 0.79 (95% CI: 0.19-0.59), an SP of 0.60 (95% CI: 0.44-0.74), and an accuracy of 0.67 (95% CI: 0.54-0.79) with an AUC of 0.68 (95% CI: 0.56-0.79). In conclusion, we found that the pooled estimate of sensitivity (SN) and specificity (SP) of FDG-PET was the highest among amnestic MCI patients in the systematic analysis. In addition, MRI and FDG-PET may complement each other depending on the characteristics of the target population.

Project Status: Completed

Year Published: 2014

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=160

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)